Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, Group expects to record a loss of about HKD 190 million as compared to a profit for the year ended 31 March 2022, which was primarily attributable to a non-cash item, resulted from a loss of about HKD 165 million arising from the fair value change of the Group's investments in convertible bonds, while a gain of about HKD 169 million due to the fair value change of the same non-cash item was incurred last year.